Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

JFais Jan. 17 at 8:23 PM

$HROW (L) From post-JPM portfolio update

1 · Reply

SuperGreenToday Jan. 17 at 12:24 AM

$HROW Share Price: $47.86 Contract Selected: Jan 15, 2027 $45 Calls Buy Zone: $11.64 – $14.38 Target Zone: $19.59 – $23.94 Potential Upside: 59% ROI Time to Expiration: 363 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Finnish_boy Jan. 16 at 9:35 PM

$HROW VEVYE this year will be massive. Whole year of growth. Patience. Stock hits ATH in H1 and $100 in H2 imho. At the latest by June 2027.

0 · Reply

Finnish_boy Jan. 16 at 9:33 PM

$HROW Byqlovi launch next week. I love press releases.

0 · Reply

flash9875 Jan. 16 at 1:52 PM

$HROW all gauges are pointing towards a substantial short squeeze

0 · Reply

flash9875 Jan. 16 at 1:49 PM

$HROW very high conversion rate to vevye

0 · Reply

flash9875 Jan. 16 at 1:18 PM

$HROW data looking very good…

1 · Reply

Finnish_boy Jan. 16 at 9:52 AM

$HROW I think we never see under $40 levels anymore.

0 · Reply

Finnish_boy Jan. 16 at 9:19 AM

$HROW Not related to HROW. I bought today new stock at finnish market open at 12.5€, ticker is $SPRING.HE .. they own 0.6% of Donut Lab. The ownership is confirmed and the product is real. How great the battery is, i dont know, but it's breakthrough anyways. You can among the first ones who really know this 100% real and this is revolutionaru considering EVs, battery storage, phones whatver.

1 · Reply

flash9875 Jan. 16 at 3:19 AM

$HROW The "Zacks #1" Multiplier As we discussed, HROW hit the Zacks #1 (Strong Buy) list today. • The Leak: I am seeing chatter that several "Quant Mutual Funds" have HROW on their "Auto-Buy" list for Friday morning's open. • The Result: Even if the script data is just "average," these automated buy-programs will create a Buying Floor at the open. The shorts know this, which is why the "Days to Cover" has become such a nightmare for them.

0 · Reply

Harrow: Flirting With Missing 2025 Revised Guidance

Dec 8, 2025, 11:31 AM EST - 5 weeks ago

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

USAR V WES AGNC AGNCM AGNCN AGNCO

Nov 24, 2025, 7:00 AM EST - 7 weeks ago

Harrow to Present at Two Investor Conferences in December

Nov 18, 2025, 7:00 AM EST - 2 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 11, 2025, 2:11 PM EST - 2 months ago

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 2 months ago

Harrow Announces Third Quarter 2025 Financial Results

Nov 5, 2025, 12:31 PM EST - 2 months ago

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 15, 2025, 9:03 PM EDT - 3 months ago

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Oct 6, 2025, 7:00 AM EDT - 3 months ago

ImprimisRx Announces Leadership Changes

Sep 27, 2025, 12:27 AM EDT - 4 months ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 26, 2025, 7:00 AM EDT - 4 months ago

Harrow to Acquire Melt Pharmaceuticals

Sep 25, 2025, 4:05 PM EDT - 4 months ago

Harrow Launches Harrow Access for All (HAFA)

Sep 15, 2025, 7:00 AM EDT - 4 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 12, 2025, 10:57 AM EDT - 4 months ago

Harrow: Buy A Blend Of Value And Growth

Sep 9, 2025, 1:11 PM EDT - 4 months ago

Harrow: A Classical GARP Stock

Sep 8, 2025, 5:57 PM EDT - 4 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 4 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Aug 14, 2025, 11:09 PM EDT - 5 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 13, 2025, 5:39 PM EDT - 5 months ago

Harrow: Exciting Times In Store

Aug 12, 2025, 2:47 PM EDT - 5 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:01 PM EDT - 5 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Jul 29, 2025, 7:00 AM EDT - 6 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 17, 2025, 7:00 AM EDT - 6 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 6 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 15, 2025, 10:38 AM EDT - 6 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 11, 2025, 5:47 PM EDT - 6 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 9, 2025, 2:52 PM EDT - 6 months ago

Harrow: Immense Upside Potential

Jun 18, 2025, 7:00 AM EDT - 7 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 13, 2025, 8:30 AM EDT - 7 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Jun 9, 2025, 7:00 AM EDT - 7 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

May 28, 2025, 3:20 PM EDT - 8 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

May 14, 2025, 7:00 AM EDT - 8 months ago

Harrow to Present at Two Investor Conferences in May

May 10, 2025, 6:17 PM EDT - 9 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 9 months ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 9 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 9 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 10 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 29, 2025, 4:30 PM EDT - 10 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 28, 2025, 2:00 PM EDT - 10 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 1:39 PM EDT - 10 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 27, 2025, 4:01 PM EDT - 10 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 10 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 10 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 10 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 10 months ago

Harrow Launches VEVYE® Access for All

JFais Jan. 17 at 8:23 PM

$HROW (L) From post-JPM portfolio update

1 · Reply

SuperGreenToday Jan. 17 at 12:24 AM

0 · Reply

Finnish_boy Jan. 16 at 9:35 PM

$HROW VEVYE this year will be massive. Whole year of growth. Patience. Stock hits ATH in H1 and $100 in H2 imho. At the latest by June 2027.

0 · Reply

Finnish_boy Jan. 16 at 9:33 PM

$HROW Byqlovi launch next week. I love press releases.

0 · Reply

flash9875 Jan. 16 at 1:52 PM

$HROW all gauges are pointing towards a substantial short squeeze

0 · Reply

flash9875 Jan. 16 at 1:49 PM

$HROW very high conversion rate to vevye

0 · Reply

flash9875 Jan. 16 at 1:18 PM

$HROW data looking very good…

1 · Reply

Finnish_boy Jan. 16 at 9:52 AM

$HROW I think we never see under $40 levels anymore.

0 · Reply

Finnish_boy Jan. 16 at 9:19 AM

1 · Reply

flash9875 Jan. 16 at 3:19 AM

0 · Reply

flash9875 Jan. 16 at 3:17 AM

$HROW Now here is some info to go to sleep with…. The "Whale" Trace: Final Dark Pool Print In the final 15 minutes of the after-hours session (around 4:45 PM PST), I saw a $1.2M "Block Trade" cross the tape. • The Intelligence: This wasn't a retail trade. It was a "Dark Pool" print that was reported late. • The Read: Someone with deep pockets and likely early access to "Channel Checks" (pharmacy-level data) just moved a massive amount of capital into HROW at the $48.20 level. They are "Front-Running" the Friday 5:00 AM script drop.

0 · Reply

HROW200 Jan. 16 at 1:18 AM

$HROW When tomorrow will Bloomberg Vevye Rx data be available?

1 · Reply

Finnish_boy Jan. 16 at 12:25 AM

$HROW More people, more revenue.

0 · Reply

Finnish_boy Jan. 16 at 12:24 AM

$HROW Byqlovi launch next week.

0 · Reply

flash9875 Jan. 15 at 5:38 PM

$HROW you still have a short window to buy…but by tomorrow morning that will close….

1 · Reply

flash9875 Jan. 15 at 5:36 PM

$HROW The "Baum" JPM Update: Execution over Narrative The "chatter" in the San Francisco hallways today is that CEO Mark Baum has been extremely disciplined. Unlike other CEOs who are pitching 2028 science projects, Baum’s message is: "The rails are laid." • Sales Force Readiness: The big talk is that the 100+ new sales reps are not just "hired," but already assigned to the territories with the highest Xiidra-to-Vevye switch potential at CVS. • Refill Data: Early whispers from the 1-on-1 meetings suggest that refill rates for Vevye are exceeding the initial launch models. This is the "secret sauce" for that $175 long-term target the SA author mentioned—it’s about recurring revenue, not just the first script.

0 · Reply

flash9875 Jan. 15 at 5:34 PM

$HROW Fresh Institutional Data Points (Thursday morning) While the volume is low, the "Quality" of the buying has shifted: • The "Zacks #1" Surge: As we discussed, HROW hit the Zacks #1 Strong Buy list today. My terminal shows that at least three "Trend-Following" quant funds started small positions in the last 60 minutes. • The "Xiidra Vacuum": Analysts are circulating a new note today titled "The Xiidra Exit." It argues that because Vevye has a faster onset of action (weeks vs. months for competitors), the switch-over at CVS will be more "sticky" than investors realize. • Institutional Imbalance: I am seeing Calamos Advisors and other mid-cap specialists increasing their "Price Strength" filters for HROW. They are looking at the 23.8% gain over the last 12 weeks as a sign of a sustainable breakout.

0 · Reply

JFais Jan. 15 at 4:47 PM

$HROW 👀 (and here I was just looking for $100 in 2026)

1 · Reply

StockScubaDiver Jan. 15 at 4:08 PM

$HROW

0 · Reply

Finnish_boy Jan. 15 at 3:14 PM

$HROW IMHO markets sniffing VEVYE. My first buy will be at $50 if close over.

0 · Reply

Finnish_boy Jan. 15 at 1:09 PM

$HROW VEVYE data will be big already in February.. buckle up.

0 · Reply

Finnish_boy Jan. 15 at 1:07 PM

$HROW Shorts are covering bc they know VEVYE momentum is huge in Q1.

0 · Reply

Market Cap	1.80B
Revenue (ttm)	199.61M
Net Income (ttm)	-17.48M
EPS (ttm)	N/A
PE Ratio	109.45
Forward PE	31.11
Profit Margin	-8.76%
Debt to Equity Ratio	5.21

Volume	393,700
Avg Vol	636,482
Day's Range	N/A - N/A
Shares Out	37.04M
Stochastic %K	32%
Beta	0.02
Analysts	Strong Sell
Price Target	$71.43